ELAVL1 and breast carcinoma: These results suggest that FAM49B knockdown can increase chemotherapy sensitivity, increase apoptosis and activation of apoptotic proteins, improve the effective rate of chemotherapy and improve the prognosis of breast cancer patients by down-regulating ELAVL1/Rab10/TLR4/NF-κB signaling pathway.